Bausch Health Cos Pre-Tax Profit Margin 2012-2025 | BHC
Bausch Health Cos pre-tax profit margin from 2012 to 2025. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Bausch Health Cos Pre-Tax Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Pre-Tax Income | Pre-Tax Margin |
| 2025-12-31 | $10.27B | $0.37B | 3.57% |
| 2025-09-30 | $10.03B | $0.52B | 5.18% |
| 2025-06-30 | $9.86B | $0.28B | 2.85% |
| 2025-03-31 | $9.73B | $0.19B | 1.94% |
| 2024-12-31 | $9.63B | $0.17B | 1.74% |
| 2024-09-30 | $9.47B | $-0.05B | -0.52% |
| 2024-06-30 | $9.20B | $-0.35B | -3.85% |
| 2024-03-31 | $8.97B | $-0.32B | -3.60% |
| 2023-12-31 | $8.76B | $-0.39B | -4.45% |
| 2023-09-30 | $8.54B | $-0.74B | -8.66% |
| 2023-06-30 | $8.35B | $0.03B | 0.30% |
| 2023-03-31 | $8.15B | $-0.18B | -2.25% |
| 2022-12-31 | $8.12B | $-0.13B | -1.59% |
| 2022-09-30 | $8.13B | $0.25B | 3.06% |
| 2022-06-30 | $8.19B | $0.03B | 0.32% |
| 2022-03-31 | $8.33B | $-0.52B | -6.19% |
| 2021-12-31 | $8.43B | $-1.02B | -12.14% |
| 2021-09-30 | $8.45B | $-1.44B | -17.03% |
| 2021-06-30 | $8.48B | $-1.58B | -18.64% |
| 2021-03-31 | $8.04B | $-1.35B | -16.75% |
| 2020-12-31 | $8.03B | $-0.93B | -11.64% |
| 2020-09-30 | $8.04B | $-2.01B | -25.01% |
| 2020-06-30 | $8.11B | $-2.15B | -26.53% |
| 2020-03-31 | $8.60B | $-1.89B | -22.02% |
| 2019-12-31 | $8.60B | $-1.84B | -21.36% |
| 2019-09-30 | $8.50B | $-0.79B | -9.33% |
| 2019-06-30 | $8.43B | $-1.03B | -12.19% |
| 2019-03-31 | $8.40B | $-1.58B | -18.83% |
| 2018-12-31 | $8.38B | $-4.15B | -49.57% |
| 2018-09-30 | $8.42B | $-4.53B | -53.81% |
| 2018-06-30 | $8.51B | $-4.63B | -54.46% |
| 2018-03-31 | $8.61B | $-4.14B | -48.08% |
| 2017-12-31 | $8.72B | $-1.74B | -19.96% |
| 2017-09-30 | $8.96B | $-1.30B | -14.47% |
| 2017-06-30 | $9.22B | $-2.23B | -24.17% |
| 2017-03-31 | $9.41B | $-2.36B | -25.12% |
| 2016-12-31 | $9.67B | $-2.44B | -25.17% |
| 2016-09-30 | $10.03B | $-2.34B | -23.36% |
| 2016-06-30 | $10.34B | $-1.02B | -9.84% |
| 2016-03-31 | $10.65B | $-0.71B | -6.62% |
| 2015-12-31 | $10.45B | $-0.16B | -1.49% |
| 2015-09-30 | $9.91B | $0.66B | 6.70% |
| 2015-06-30 | $9.18B | $1.05B | 11.40% |
| 2015-03-31 | $8.49B | $1.23B | 14.52% |
| 2014-12-31 | $8.21B | $1.06B | 12.86% |
| 2014-09-30 | $8.05B | $0.43B | 5.28% |
| 2014-06-30 | $7.53B | $-1.09B | -14.51% |
| 2014-03-31 | $6.59B | $-1.25B | -19.03% |
| 2013-12-31 | $5.77B | $-1.31B | -22.77% |
| 2013-09-30 | $4.63B | $-1.51B | -32.66% |
| 2013-06-30 | $3.97B | $-0.46B | -11.57% |
| 2013-03-31 | $3.69B | $-0.44B | -11.81% |
| 2012-12-31 | $3.48B | $-0.39B | -11.32% |
| 2012-09-30 | $3.21B | $-0.20B | -6.10% |
| 2012-06-30 | $2.93B | $-0.10B | -3.24% |
| 2012-03-31 | $2.72B | $-0.03B | -1.25% |
| 2011-12-31 | $2.43B | $-0.02B | -0.74% |
| 2011-09-30 | $2.29B | $-0.08B | -3.28% |
| 2011-06-30 | $1.90B | $-0.24B | -12.39% |
| 2011-03-31 | $1.53B | $-0.24B | -15.72% |
| 2010-12-31 | $1.18B | $-0.24B | -20.05% |
| 2010-09-30 | $0.91B | $-0.06B | -6.06% |
| 2010-06-30 | $0.91B | $0.14B | 15.44% |
| 2010-03-31 | $0.87B | $0.13B | 14.98% |
| 2009-12-31 | $0.82B | $0.18B | 21.32% |
| 2009-09-30 | $0.76B | $0.16B | 20.89% |
| 2009-06-30 | $0.73B | $0.16B | 22.50% |
| 2009-03-31 | $0.72B | $0.12B | 16.09% |
| 2008-12-31 | $0.76B | $0.13B | 16.80% |
| 2008-09-30 | $0.78B | $0.06B | 8.22% |
| 2008-06-30 | $0.79B | $0.08B | 10.17% |
| 2008-03-31 | $0.80B | $0.17B | 21.39% |
| 2007-12-31 | $0.84B | $0.21B | 24.79% |
| 2007-09-30 | $0.95B | $0.36B | 37.70% |
| 2007-06-30 | $1.05B | $0.24B | 22.42% |
| 2007-03-31 | $1.10B | $0.25B | 22.68% |
| 2006-12-31 | $1.07B | $0.22B | 20.80% |
| 2006-09-30 | $1.05B | $0.27B | 25.29% |
| 2006-06-30 | $1.02B | $0.44B | 42.84% |
| 2006-03-31 | $0.98B | $0.33B | 33.64% |
| 2005-12-31 | $0.94B | $0.27B | 28.78% |
| 2005-09-30 | $0.93B | $0.16B | 17.24% |
| 2005-06-30 | $0.89B | $0.09B | 10.61% |
| 2005-03-31 | $0.88B | $0.16B | 18.29% |
| 2004-12-31 | $0.89B | $0.17B | 19.17% |
| 2004-09-30 | $0.81B | $0.00B | 0.00% |
| 2004-06-30 | $0.81B | $-0.04B | -4.46% |
| 2004-03-31 | $0.82B | $-0.08B | -9.40% |
| 2003-12-31 | $0.82B | $-0.03B | -3.77% |
| 2003-09-30 | $0.86B | $-0.01B | -0.81% |
| 2003-06-30 | $0.86B | $0.06B | 6.78% |
| 2003-03-31 | $0.82B | $0.12B | 14.56% |
| 2002-12-31 | $0.79B | $0.11B | 13.83% |
| 2002-09-30 | $0.73B | $0.20B | 27.51% |
| 2002-06-30 | $0.67B | $0.16B | 23.28% |
| 2002-03-31 | $0.62B | $0.13B | 20.68% |
| 2001-12-31 | $0.58B | $0.10B | 17.67% |
| 2001-09-30 | $0.51B | $0.29B | 56.63% |
| 2001-06-30 | $0.44B | $0.15B | 33.71% |
| 2001-03-31 | $0.37B | $0.13B | 36.41% |
| 2000-12-31 | $0.30B | $0.12B | 39.19% |
| 2000-09-30 | $0.26B | $-0.03B | -12.21% |
| 2000-06-30 | $0.22B | $0.09B | 39.27% |
| 2000-03-31 | $0.20B | $0.08B | 38.46% |
| 1999-12-31 | $0.18B | $0.07B | 39.77% |
| 1999-09-30 | $0.15B | $0.06B | 37.41% |
| 1999-06-30 | $0.13B | $0.05B | 39.23% |
| 1999-03-31 | $0.12B | $0.05B | 40.34% |
| 1998-12-31 | $0.11B | $0.05B | 41.59% |
| 1998-09-30 | $0.10B | $0.06B | 56.86% |
| 1998-06-30 | $0.09B | $0.07B | 69.15% |
| 1998-03-31 | $0.09B | $0.06B | 71.26% |
| 1997-12-31 | $0.08B | $0.06B | 74.07% |
| 1997-09-30 | $0.07B | $0.05B | 66.67% |
| 1997-06-30 | $0.07B | $0.03B | 46.97% |
| 1997-03-31 | $0.07B | $0.03B | 45.45% |
| 1996-12-31 | $0.07B | $0.04B | 58.21% |
| 1996-09-30 | $0.06B | $0.04B | 58.06% |
| 1996-06-30 | $0.05B | $0.03B | 70.21% |
| 1996-03-31 | $0.03B | $0.03B | 93.75% |
| 1995-12-31 | $0.02B | $0.02B | 100.00% |
| 1995-09-30 | $0.02B | $0.02B | 100.00% |
| 1995-06-30 | $0.02B | $0.02B | 100.00% |
| 1995-03-31 | $0.02B | $0.02B | 85.71% |
| 1994-12-31 | $0.02B | $0.01B | 82.35% |
| 1994-06-30 | $0.01B | $0.00B | 22.22% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.086B | $10.266B |
| Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |